Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. has been granted 287 US utility patents between 2015 and 2025, placing Alnylam Pharmaceuticals, Inc. at rank #1,451 across all assignees tracked by PlainPatent. This portfolio spans 23 distinct Cooperative Patent Classification (CPC) subclasses, averaging 26.0 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a US Corporation, Alnylam Pharmaceuticals, Inc. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 56.4/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 155 grants, compared with 132 in the 2015–2019 window — a +17% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Alnylam Pharmaceuticals, Inc.'s 26.0 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while a multi-domain presence across 23 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Alnylam Pharmaceuticals, Inc. against peers pursuing similar technology classes.